<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This multicenter, open-label study evaluated the efficacy and safety of <z:chebi fb="0" ids="50131">decitabine</z:chebi> in patients from Argentina and South Korea with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Of 106 patients who received <z:chebi fb="0" ids="50131">decitabine</z:chebi> 20 mg/m(2) intravenously over 1â€‰h once daily for 5 days in 4-week cycles, 99 patients were evaluable after receiving at least two cycles </plain></SENT>
<SENT sid="2" pm="."><plain>The overall improvement rate was 35% (19% complete response +4% marrow complete response +4% partial response +8% hematologic improvement) </plain></SENT>
<SENT sid="3" pm="."><plain>Overall survival at 2 years was 71% </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment-related adverse events included febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and <z:mp ids='MP_0001914'>bleeding</z:mp>, asthenia, <z:mp ids='MP_0002899'>fatigue</z:mp>, and <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>After complete response (CR), three patients received an allogeneic stem cell transplant </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients who relapsed after CR responded to <z:chebi fb="0" ids="50131">decitabine</z:chebi> retreatment </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0004808'>Acute myelogenous leukemia</z:hpo> developed during follow-up in 21% of patients </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> in a 5-day outpatient administration schedule was effective and well tolerated in typical clinical practice settings in South America and Asia </plain></SENT>
</text></document>